- The FDA has approved Novartis AG's NVS Tafinlar (dabrafenib) + Mekinist (trametinib) for pediatric patients one year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.
- LGG is the most common pediatric brain cancer. BRAF V600 mutations are present in 15-20% of pediatric LGGs.
- The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age.
- These approvals make Tafinlar + Mekinist the first and only approved combination targeted therapy to treat pediatric patients with BRAF V600E LGG.
- Also Read: Novartis' Prostate Cancer Therapy Hit By Supply Crunch, Seeks To Ramp Up Production To Ease Supply Issues.
- The FDA approval is based on results from the Phase 2/3 TADPOLE trial. Patients randomized to receive Tafinlar + Mekinist experienced a statistically significant improvement in overall response rate (ORR) of 47% compared to 11% for those randomized to receive chemotherapy.
- At a median follow-up of 18.9 months, median progression-free survival (PFS) was 20.1 months with Tafinlar + Mekinist compared to 7.4 months with chemotherapy.
- This FDA approval is the sixth for Tafinlar + Mekinist, which is indicated across multiple BRAF V600 solid tumors, including melanoma, thyroid, and lung cancer.
- Price Action: NVS shares are up 0.57% at $83.25 during the premarket session on the last check Friday.
- Photo Via Company
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
